Bioprinting holds enormous promise in medicine in areas such as tissue engineering, regenerative medicine and drug discovery. AXT has identified the potential for this technology to print tissues and even organs and has partnered with REGENHU to offer their unique bioprinters to Australian and New Zealand researchers.
REGENHU is a research driven Swiss MedTech bioprinter pioneer committed to assisting the research and scientific communities by creating and developing state-of-the art bioprinting technologies to revolutionise medicine. Founded in 2007, the dynamic and rapidly expanding company is based in VIllaz-St-Pierre, Switzerland with offices in the United States and distributors in Asia and Oceania.
Known for their modular and flexible solutions, REGENHU’s bioprinters can be easily customised to suit even the most demanding requirements and are used in applications ranging from drug discovery to tablet formulation. Recently, the company launched the REGENHU bioprinting platform, comprising of two next generation bioprinters, the R-GEN 100 and R-GEN 200, and SHAPER, its software, covering the entire fabrication process.
Installations at pharmaceutical companies such as L’Oreal, DePuy Synthes and Glaxo Smith Kline, as well as universities around the world including Chalmers University of Technology, National University of Singapore, Queen Mary University of London and many more as well as an extensive list of journal publications are a testament to the capabilities of REGENHU’s bioprinters.
Simon MacKenzie, CEO of from REGENHU commented “We are excited to announce that AXT PTY LTD is now our official distributor in Australia and New Zealand! Together with AXT PTY LTD, we are committed to supporting the scientific community advancing science and taking their research to the next level through our innovative technologies and solutions. “
Richard Trett, Managing Director at AXT added, “we see enormous potential for bioprinting technology in the Australian research community and firmly believe that REGENHU’s flexible platform is an ideal system for researchers looking for a high-performance, flexible solution.”
For more information about REGENHU’s bioprinters and AXT’s other related life science products, please visit www.axt.com.au